Navitoclax (ABT-263)

Catalog No.S1001

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Cited by 93 Publications

Cell, 2019, 178(2):302-315.e23

PubMed: 31299200 ( click the link to review the publication )

Cell, 2019, 178(2):361-373

PubMed: 31204100 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 36(1):68-83

PubMed: 31257073 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(3):407-414.e4

PubMed: 28017795 ( click the link to review the publication )

Nature, 2016, 538(7626):477-482

PubMed: 27760111 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1398

PubMed: 31492749 ( click the link to review the publication )

Thyroid, 2019, 29(4):540-548

PubMed: 30869573 ( click the link to review the publication )

Oncogene, 2019, 38(1):47-59

PubMed: 30076411 ( click the link to review the publication )

Br J Pharmacol, 2019, 10.1111/bph.14773

PubMed: 31222722 ( click the link to review the publication )

Cell Death Dis, 2019, 10(5):342

PubMed: 31019203 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.04.011

PubMed: 31155509 ( click the link to review the publication )

Stem Cell Res Ther, 2019, 10(1):86

PubMed: 30867061 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5912

PubMed: 30976015 ( click the link to review the publication )

Prostate, 2019, 79(11):1347-1359

PubMed: 31228231 ( click the link to review the publication )

Transl Oncol, 2019, 12(4):683-692

PubMed: 30844579 ( click the link to review the publication )

Cancer Biomark, 2019, 24(1):51-59

PubMed: 30614795 ( click the link to review the publication )

Cell Oncol (Dordr), 2019, 42(3):287-301

PubMed: 30859392 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(19):10195-10215

PubMed: 30239926 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):21

PubMed: 29343814 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):907

PubMed: 30185782 ( click the link to review the publication )
Stem Cell Res Ther, 2018, 9(1):108

PubMed: 29669575 ( click the link to review the publication )

Antioxidants (Basel), 2018, 10.3390/antiox7110150

PubMed: 30373097 ( click the link to review the publication )

Biochemical Pharmacology, 2018, 10.1016/j.bcp.2018.01.031

PubMed: ( click the link to review the publication )

Biomed Pharmacother, 2018, 107:139-145

PubMed: 30086460 ( click the link to review the publication )

Toxicol In Vitro, 2018, 46:229-236

PubMed: 28947240 ( click the link to review the publication )

Cancer Res, 2017, 77(8):2018-2028

PubMed: 28202526 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3513-3526

PubMed: 28522750 ( click the link to review the publication )

Cancer Res, 2017, 77(9):2476-2487

PubMed: 28209615 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2178-2190

PubMed: 28611106 ( click the link to review the publication )

Cell Commun Signal, 2017, 15(1):16

PubMed: 28464919 ( click the link to review the publication )

Dis Model Mech, 2017, 10(9):1109-1115

PubMed: 28883017 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(12):1632-1641

PubMed: 28713162 ( click the link to review the publication )

Int J Oncol, 2017, 10.3892/ijo.2017.3914

PubMed: 28350129 ( click the link to review the publication )

Biomed Pharmacother, 2017, 95:1574-1579

PubMed: 28950657 ( click the link to review the publication )

Anticancer Drugs, 2017, 28(10):1141-1149

PubMed: 28885267 ( click the link to review the publication )

Oncotarget, 2017, 8(34):57047-57057

PubMed: 28915653 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Clin Cancer Res, 2016, pii: clincanres.2827.2015

PubMed: 27126996 ( click the link to review the publication )

Leukemia, 2016, 30(2):351-60

PubMed: 26488112 ( click the link to review the publication )

Cancer Res, 2016, 76(23):7001-7011

PubMed: 27671680 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Anal Chem, 2016, 88(16):8050-7

PubMed: 27425825 ( click the link to review the publication )

Endocr Relat Cancer, 2016, 23(1):35-45

PubMed: 26483423 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(4):1792-7

PubMed: 27613092 ( click the link to review the publication )
J Biomol Screen, 2016, 21(7):680-8

PubMed: 27245141 ( click the link to review the publication )

Mol Med Rep, 2016, 13(1):403-11

PubMed: 26548896 ( click the link to review the publication )

Data Brief, 2016, 6:710-4

PubMed: 26958630 ( click the link to review the publication )

Cell Death Differ, 2015, 10.1038/cdd.2015.73

PubMed: 26045046 ( click the link to review the publication )

Breast Cancer Res, 2015, 17:26

PubMed: 25848915 ( click the link to review the publication )

Breast Cancer Res, 2015, 17(1):533

PubMed: 25778369 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(1):298-306

PubMed: 25344583 ( click the link to review the publication )

Frontiers in Oncology, 2015, 4:368

PubMed: 25566506 ( click the link to review the publication )

Ann Surg Oncol, 2015, 22(9):3079-86

PubMed: 25524010 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0120913

PubMed: 25811469 ( click the link to review the publication )

Microvasc Res, 2015, 101:72-81

PubMed: 26122935 ( click the link to review the publication )

J Clin Invest, 2014, 124(1):117-28

PubMed: 24292713 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):4737-52

PubMed: 25250573 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(41):14788-93

PubMed: 25267614 ( click the link to review the publication )

Chem Sci, 2014, 5, 2794–2803

PubMed: ( click the link to review the publication )

Int J Cancer, 2014, 136(3):688-98

PubMed: 24895203 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.21

PubMed: 24608435 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1291

PubMed: 24922075 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02798-13

PubMed: 24752266 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574 ( click the link to review the publication )

Skelet Muscle, 2014, 4(1):4

PubMed: 24484587 ( click the link to review the publication )

PLoS One, 2014, 9(10):e108371

PubMed: 25289887 ( click the link to review the publication )
PLoS One, 2014, ;9(6):e99404

PubMed: 24901320 ( click the link to review the publication )

Blood, 2013, 121(10):1850-7

PubMed: 23303820 ( click the link to review the publication )

Blood, 2013, 122(9):1587-98

PubMed: 23881917 ( click the link to review the publication )

Cell Death Differ, 2013, 20(11):1475-84

PubMed: 23832116 ( click the link to review the publication )

Int J Cancer, 2013, 132(4):978-87

PubMed: 22821746 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e883

PubMed: 24157877 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Neoplasia, 2013, 15(5):568-78

PubMed: 23633928 ( click the link to review the publication )

Exp Dermatol, 2013, 22(8):518-23

PubMed: 23802633 ( click the link to review the publication )

Helsinki Metropolia University, 2013, Jens Desloovere

PubMed: ( click the link to review the publication )

Cancer Res, 2012, 72(12):2949-56

PubMed: 22505651 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Cancer Lett, 2012, 339(2):288-97

PubMed: 23200668 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e351

PubMed: 22825469 ( click the link to review the publication )

J Biol Chem, 2012, 287(34):28598-608

PubMed: 22733819 ( click the link to review the publication )

Mol Biol Cell, 2012, 23(12):2240-52

PubMed: 22535522 ( click the link to review the publication )

Transfusion, 2012, 52(10):2094-103

PubMed: 22320126 ( click the link to review the publication )

Blood, 2011, 117(26):7145-54

PubMed: 21562047 ( click the link to review the publication )

PLoS One, 2011, 6(9):e24590

PubMed: 21931768 ( click the link to review the publication )

Biochem Biophys Res Commun, 2011, 408(2):344-9

PubMed: 21514278 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(16):4217-25

PubMed: 20601444 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Targets

Bcl-xL ^[1] (Cell-free assay)	Bcl-2 ^[1] (Cell-free assay)	Bcl-w ^[1] (Cell-free assay)
<=0.5 nM(Ki)	<=1 nM(Ki)	<=1 nM(Ki)

In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. ^[1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. ^[1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. ^[2]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
EoL-1-cell	Ml;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfJV4xKSzVyPUCuNFA3PjlizszN	NIrJZWtUSU6JRWK=
MV-4-11	M{n4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PT[2lEPTB;MD6wNVU5PiEQvF2=	MYfTRW5ITVJ?
NKM-1	NWr2VGl7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXPXVFKSzVyPUCuNFE3QTlizszN	M2Lh[3NCVkeHUh?=
ML-2	M1LN[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLUTWM2OD1yLkCxPVg{KM7:TR?=	Mn7zV2FPT0WU
BV-173	NWnYRllHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXHemIyUUN3ME2wMlAzOzF2IN88US=>	M3\aOXNCVkeHUh?=
RS4-11	NXHVVlR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHiR2M4UUN3ME2wMlAzPTh5IN88US=>	NFXFdlJUSU6JRWK=
HL-60	NHPObllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXKTWM2OD1yLkCyPVA5KM7:TR?=	NH64SZdUSU6JRWK=
KY821	NUHYZYJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTBwMEK5O\|Uh\|ryP	NH3YNI1USU6JRWK=
ECC10	NH:2c2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnrxTWM2OD1yLkCzO\|kzKM7:TR?=	Moj0V2FPT0WU
NCI-H720	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzncmtIUUN3ME2wMlA1ODFzIN88US=>	MWfTRW5ITVJ?
QIMR-WIL	NXrVWIN1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFS5NXpKSzVyPUCuNFQzQDdizszN	MUjTRW5ITVJ?
KG-1	Ml\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NESycYlKSzVyPUCuNFQ1QDZizszN	MULTRW5ITVJ?
TGW	M3rCRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLJOXBKUUN3ME2wMlA1PjN\|IN88US=>	MV7TRW5ITVJ?
ATN-1	NYHFe3dZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{izbWlEPTB;MD6wOFc{OyEQvF2=	MWjTRW5ITVJ?
RH-18	NHu0cXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LJRWlEPTB;MD6wOlA1QCEQvF2=	NV3ETmd2W0GQR1XS
EW-18	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTBwME[4OFEh\|ryP	MXHTRW5ITVJ?
NB17	M1;0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTBwMEexNlQh\|ryP	NHPPTVFUSU6JRWK=
SK-NEP-1	NIPDVoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTIeo5jUUN3ME2wMlA4OjF\|IN88US=>	NXLaVZk6W0GQR1XS
P12-ICHIKAWA	MnXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1y2bWlEPTB;MD6wO\|c4QCEQvF2=	MlLlV2FPT0WU
KARPAS-45	MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoW0TWM2OD1yLkC3PFE2KM7:TR?=	NG\BPVVUSU6JRWK=
EW-3	M4[1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXqS3F1UUN3ME2wMlA5ODV\|IN88US=>	MY\TRW5ITVJ?
NB13	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoG2TWM2OD1yLkC4NlA{KM7:TR?=	NH76TWhUSU6JRWK=
NCI-H209	NG\aZ2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHL6Z5RKSzVyPUCuNFg4ODRizszN	MkHlV2FPT0WU
NCI-H1092	NHjTU2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTBwMUCyO\|Uh\|ryP	MWDTRW5ITVJ?
NH-12	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnTWTWM2OD1yLkGwO\|Q1KM7:TR?=	M4H6fHNCVkeHUh?=
697	NE\DcJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoWxTWM2OD1yLkGwPFM6KM7:TR?=	MXzTRW5ITVJ?
KE-37	M2r1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\STWM2OD1yLkGxN\|ch\|ryP	NX[1Sm06W0GQR1XS
MOLT-4	M{G1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXOxfmxzUUN3ME2wMlE2OTZ7IN88US=>	NWHqdIVCW0GQR1XS
CHP-134	MmnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPER49KSzVyPUCuNVY{ODZizszN	M3\5NXNCVkeHUh?=
D-283MED	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\SR2lEPTB;MD6xO\|Y5PiEQvF2=	MWLTRW5ITVJ?
LU-135	MkLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTBwMUi1OVIh\|ryP	NVX6T\|RTW0GQR1XS
LU-134-A	M2HtOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HWe2lEPTB;MD6xPFY4OSEQvF2=	NXvuWZg1W0GQR1XS
EM-2	M4XFd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGrZOFdKSzVyPUCuNVk6OThizszN	MULTRW5ITVJ?
LU-139	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnQSXpKSzVyPUCuNlA1QThizszN	MXPTRW5ITVJ?
ALL-PO	NGjiepZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTBwMkG5PFgh\|ryP	Mk\IV2FPT0WU
NB12	MlfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlGxTWM2OD1yLkKzNVE2KM7:TR?=	MXLTRW5ITVJ?
KP-N-YN	M1LlOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrETWM2OD1yLkKzOVc{KM7:TR?=	NVjBSFNiW0GQR1XS
BEN	NH3YXm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3nmdGlEPTB;MD6yN\|k3QCEQvF2=	NFTIRXNUSU6JRWK=
HCC1569	M2nX[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mln5TWM2OD1yLkK1NVA3KM7:TR?=	Mlm2V2FPT0WU
HuO9	NYDhO3NjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTBwMk[3NVUh\|ryP	NInNSJNUSU6JRWK=
WM-115	NEjoTolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGLSUnVKSzVyPUCuNlc4OzhizszN	NFLmUVhUSU6JRWK=
CCRF-CEM	NFjNfGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4X3N2lEPTB;MD6zN\|UzQSEQvF2=	NISxOIJUSU6JRWK=
IST-SL1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\VTWM2OD1yLkO1N\|Q{KM7:TR?=	M4G0enNCVkeHUh?=
BE-13	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{f3cmlEPTB;MD6zOlQ2QSEQvF2=	MY\TRW5ITVJ?
COR-L88	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnQeXpKSzVyPUCuN\|Y2PCEQvF2=	M{fITnNCVkeHUh?=
DOHH-2	NX7pWnNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfTTWM2OD1yLkSxNFI{KM7:TR?=	MlXUV2FPT0WU
A704	M1;adGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFH4UoxKSzVyPUCuOFI3PyEQvF2=	NGfST3lUSU6JRWK=
KNS-81-FD	M3n3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTBwNESwNVch\|ryP	MmjZV2FPT0WU
RPMI-8226	NW\WdYtuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUfjfGQxUUN3ME2wMlQ2PjV{IN88US=>	M33Bd3NCVkeHUh?=
TGBC24TKB	NF\wU45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV33dFFKUUN3ME2wMlQ2Pzd6IN88US=>	NXLFSpRZW0GQR1XS
NCI-H1304	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTBwNE[xOVch\|ryP	Mo\GV2FPT0WU
MOLT-13	M2j2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTBwNE[2NVMh\|ryP	M1;jSXNCVkeHUh?=
EW-22	NI\0RYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHjaeXBKSzVyPUCuOFY3PzFizszN	MUXTRW5ITVJ?
MS-1	NV25Roo{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTBwNE[5N\|Mh\|ryP	NXvkbng2W0GQR1XS
RMG-I	M2nvc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTBwNEm0OlQh\|ryP	MkniV2FPT0WU
NTERA-S-cl-D1	NIrZPJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlz4TWM2OD1yLkWwNFE6KM7:TR?=	MYDTRW5ITVJ?
NCI-H1048	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTBwNUC5OVMh\|ryP	M33Fe3NCVkeHUh?=
SW1417	NGTiTGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHzRph6UUN3ME2wMlU2PDN6IN88US=>	Ml\LV2FPT0WU
DB	NInQ[YFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPt[WRKSzVyPUCuOVcxQCEQvF2=	Mnf5V2FPT0WU
MEG-01	M2\oNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjxNlBKSzVyPUCuOVg{OiEQvF2=	MnrUV2FPT0WU
EW-13	NVLqN3hWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYqzOXg{UUN3ME2wMlU5OzRzIN88US=>	NHjrSGFUSU6JRWK=
LAMA-84	NH[3T2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fLZWlEPTB;MD61PVIxPyEQvF2=	MX\TRW5ITVJ?
J-RT3-T3-5	M4T4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\lO2lEPTB;MD62NFgxQCEQvF2=	M3juNHNCVkeHUh?=
MOLT-16	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTBwNkWyOlQh\|ryP	NXTQR5BmW0GQR1XS
DU-4475	NICyV2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVmwR3VOUUN3ME2wMlY2PDJ5IN88US=>	NWPtN5U4W0GQR1XS
HAL-01	NHfEcphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYXJR\|UxRTBwN{K1OFkh\|ryP	MlLUV2FPT0WU
RD	MnvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYfCc2FyUUN3ME2wMlc2QDl7IN88US=>	MUjTRW5ITVJ?
OAW-28	NWi3SIhyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnr2TWM2OD1yLke4N\|ch\|ryP	MV\TRW5ITVJ?
HCC38	NV61R3hQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTBwOECxPUDPxE1?	MWDTRW5ITVJ?
NMC-G1	NYLyfpF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTwSVAxUUN3ME2wMlgyOTJzIN88US=>	NEfIeHZUSU6JRWK=
EW-16	MkfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTBwOEGzNlgh\|ryP	MljXV2FPT0WU
DU-145	M3;XNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEf2[ZJKSzVyPUCuPFk6OjNizszN	M4W5N3NCVkeHUh?=
HPAF-II	NEfrW\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\LTWM2OD1yLkmyOlI5KM7:TR?=	NFnXU2VUSU6JRWK=
A427	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTBwOUOwNlIh\|ryP	M1m4e3NCVkeHUh?=
PA-1	NX;zemh5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLCTWM2OD1yLkm1OlQzKM7:TR?=	MoDwV2FPT0WU
OAW-42	NGjI[pRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHWeGxGUUN3ME2wMlk3OTR4IN88US=>	MorrV2FPT0WU
L-428	NX;N[Y9uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3G5R2lEPTB;MT6wNVI2KM7:TR?=	MWTTRW5ITVJ?
COLO-824	NILmOGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3CR2RKSzVyPUGuNFE4ODhizszN	NW\4bWI4W0GQR1XS
P30-OHK	NYfSb\|hvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrRXm5uUUN3ME2xMlA1Pjh6IN88US=>	MkfWV2FPT0WU
NCI-H2170	Ml7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTFwME[yN{DPxE1?	M175RXNCVkeHUh?=
HCC2998	NYq4OoVJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTFwMEexN\|Uh\|ryP	MlrnV2FPT0WU
NB14	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTFwMUO3OFgh\|ryP	NUDZWmJ1W0GQR1XS
TGBC1TKB	MkjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHFdmRKSzVyPUGuNVQyPTJizszN	NYfaeIVxW0GQR1XS
KP-N-YS	NXjZcJpVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWe0TI5vUUN3ME2xMlE3OjN4IN88US=>	Ml7aV2FPT0WU
CAL-120	NVTyb3lvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUPJR\|UxRTFwMU[0Nlkh\|ryP	NX7Re5FXW0GQR1XS
SBC-1	NEC3bGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHi3N2lKSzVyPUGuNVkxPTNizszN	M3faOnNCVkeHUh?=
C32	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DZUmlEPTB;MT6xPVA5QCEQvF2=	M3rTbnNCVkeHUh?=
HCC2157	NUfG[JNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU[3TGQ5UUN3ME2xMlE6PDl2IN88US=>	MlPJV2FPT0WU
COLO-792	NEi3[4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGfK[FhKSzVyPUGuNlAxPzFizszN	MlPVV2FPT0WU
ES7	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTFwMke5OVEh\|ryP	NFfscllUSU6JRWK=
HEL	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVWzOllWUUN3ME2xMlMyODJ7IN88US=>	MVzTRW5ITVJ?
ES4	MkO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGP1S5RKSzVyPUGuN\|Q6QThizszN	MoXxV2FPT0WU
NCI-SNU-1	MnnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLETWM2OD1zLkO2OVU2KM7:TR?=	NEHBOHdUSU6JRWK=
MDA-MB-415	NIm2XFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1i0U2lEPTB;MT6zPFg2KM7:TR?=	MmntV2FPT0WU
NCI-H2342	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXrfYxyUUN3ME2xMlQxOjZ7IN88US=>	MYjTRW5ITVJ?
NB69	Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTFwNE[yO\|Eh\|ryP	MUfTRW5ITVJ?
D-247MG	NW\1UIVST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jJdWlEPTB;MT61NVEzOiEQvF2=	M4jmOXNCVkeHUh?=
SCC-4	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NES1[VhKSzVyPUGuOVk5QDdizszN	NXHDb2duW0GQR1XS
HuH-7	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXlTWM2OD1zLk[3Nlk{KM7:TR?=	NGrH[ndUSU6JRWK=
A388	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTFwNki3NlQh\|ryP	M3ToZnNCVkeHUh?=
Calu-3	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\KTWM2OD1zLkewOlk4KM7:TR?=	MmPIV2FPT0WU
NCI-H1648	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHT2[oFKSzVyPUGuO\|E1OThizszN	MlnBV2FPT0WU
NCI-H2052	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnn0TWM2OD1zLkeyNlAyKM7:TR?=	NHrQZ2FUSU6JRWK=
Ramos-2G6-4C10	NYj2bpZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fMZWlEPTB;MT63N\|Y2PiEQvF2=	M4jofXNCVkeHUh?=
DEL	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\RUWlEPTB;MT63OFY6OiEQvF2=	MmXRV2FPT0WU
SNU-423	Mlj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLwd\|YyUUN3ME2xMlc5OTV5IN88US=>	Ml7KV2FPT0WU
COR-L23	M1PkVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLXTWM2OD1zLke5PFc1KM7:TR?=	Mn\UV2FPT0WU
OMC-1	MmLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mln3TWM2OD1zLki2NFE3KM7:TR?=	MX\TRW5ITVJ?
EW-11	Mk\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MknRTWM2OD1zLkm1OlU4KM7:TR?=	MXjTRW5ITVJ?
HSC-3	NX\sXJA2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHn4NItKSzVyPUGuPVY{PjVizszN	MX\TRW5ITVJ?
MLMA	MnzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TqWGlEPTB;MT65OlY4PyEQvF2=	NEPxNo9USU6JRWK=
RCM-1	NHXz[5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYqzRnVGUUN3ME2yMlAxOzl7IN88US=>	M{DNOXNCVkeHUh?=
MFE-280	NIq1OVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTJwMEK4OFgh\|ryP	NIGxfFhUSU6JRWK=
ES8	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGe4NoNKSzVyPUKuNlU1PzFizszN	NIjMUJlUSU6JRWK=
TE-11	M3v0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1f5Z2lEPTB;Mj6yPVQ4OyEQvF2=	M4H6b3NCVkeHUh?=
HuO-3N1	NHj1bWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mne3TWM2OD1{LkS4O\|gh\|ryP	M{LGNnNCVkeHUh?=
MHH-NB-11	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NImzcnZKSzVyPUKuOVEyPThizszN	NH7McIpUSU6JRWK=
TGBC11TKB	MoTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PndmlEPTB;Mj61O\|Y5OSEQvF2=	MWPTRW5ITVJ?
HOP-92	MkPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnXTWM2OD1{LkW4O\|Q{KM7:TR?=	NIDnOJNUSU6JRWK=
IGR-1	M{[wUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MneyTWM2OD1{Lk[yNFM2KM7:TR?=	MnPmV2FPT0WU
GOTO	M1THO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXzxUoVQUUN3ME2yMlY2Ozd5IN88US=>	MljGV2FPT0WU
NCI-H1650	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnGTWM2OD1{LkeyNlE2KM7:TR?=	MlfHV2FPT0WU
NCI-H1581	MmnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrqO4xKSzVyPUKuO\|k3QDFizszN	NFHaTJJUSU6JRWK=
NCI-H2405	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NULvcnRHUUN3ME2yMlgzPzh{IN88US=>	NGrQUWhUSU6JRWK=
U-118-MG	M{W5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrRTWM2OD1{Lkm2OFkyKM7:TR?=	NVTENIJvW0GQR1XS
DoTc2-4510	Ml33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{i5ZmlEPTB;Mz6wNVQyPyEQvF2=	MkLpV2FPT0WU
NCI-H596	Mkm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWO4WIZsUUN3ME2zMlA1QTl5IN88US=>	NHnyPZlUSU6JRWK=
MPP-89	NVH4[mtzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3ETWM2OD1\|LkC1OlY3KM7:TR?=	M4OyPXNCVkeHUh?=
GCIY	NVzkSGZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fnfmlEPTB;Mz6yNFQ6OSEQvF2=	MU\TRW5ITVJ?
SW626	NUTYZXRkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInUTJVKSzVyPUOuNlQ2PDNizszN	M{nVWHNCVkeHUh?=
OCI-AML2	NUTK[3JKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvC[WdKSzVyPUOuN\|EzPzJizszN	M1y4RXNCVkeHUh?=
NBsusSR	NHrmPZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4P0[mlEPTB;Mz6zOFk{QCEQvF2=	NHPCR5NUSU6JRWK=
AN3-CA	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33q[2lEPTB;Mz60OFI{QCEQvF2=	M2DVZ3NCVkeHUh?=
EFM-19	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjXTWM2OD1\|LkS4N\|M6KM7:TR?=	NUP3N2tEW0GQR1XS
RVH-421	M{\zVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnyTIl6UUN3ME2zMlU3QDd5IN88US=>	NVu0V5lkW0GQR1XS
5637	M3jK[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVS1N3lrUUN3ME2zMlYyOTB\|IN88US=>	NHPYV4xUSU6JRWK=
PANC-08-13	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIWxbohKSzVyPUOuOlM1PzJizszN	NYDuWG5MW0GQR1XS
H9	M3e0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULaR5NUUUN3ME2zMlY4OTR2IN88US=>	MWXTRW5ITVJ?
KARPAS-299	M4LheGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTNwNkezOlEh\|ryP	Mmi5V2FPT0WU
TE-5	NUDkVoV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHXTWM2OD1\|LkewO\|A6KM7:TR?=	NVn3c4pDW0GQR1XS
NOS-1	Mn;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDrPI5KSzVyPUOuO\|k5OzRizszN	MmrVV2FPT0WU
HH	Ml;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHzHXoRKSzVyPUOuPFM5PjhizszN	M365d3NCVkeHUh?=
769-P	M3rRPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYr4colpUUN3ME2zMlg6PTFizszN	NHfHUG1USU6JRWK=
CHP-212	MmH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlm4TWM2OD1\|LkmyOVQ6KM7:TR?=	NXHK[nRVW0GQR1XS
NCI-H82	M3rlWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3GSXpKSzVyPUOuPVU6OzZizszN	M2G0VHNCVkeHUh?=
Mo-T	NGXrN\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\GTWM2OD12LkC0N\|EzKM7:TR?=	MofCV2FPT0WU
BB65-RCC	NHvaXXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fIXWlEPTB;ND6wOFM6QSEQvF2=	NFPrWYNUSU6JRWK=
SW1990	M{LJeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIS5Sm1KSzVyPUSuNFU6ODhizszN	NUnafFFvW0GQR1XS
LK-2	NFTUZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fENWlEPTB;ND6xNVI6OyEQvF2=	M2n2R3NCVkeHUh?=
ES5	NFzUbIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTRwMUO5PFUh\|ryP	NWTiW5M2W0GQR1XS
JVM-3	NGDZSnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTRwMUiyNlIh\|ryP	NWHOW2tTW0GQR1XS
RPMI-7951	NWfKeoh7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NILqRYhKSzVyPUSuNlI1OTNizszN	MYXTRW5ITVJ?
Calu-6	M2\UOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTRwMke4PFEh\|ryP	NVHMbI52W0GQR1XS
LC-2-ad	M2HPS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLBOJlKSzVyPUSuNlk2PjhizszN	MnX6V2FPT0WU
SW954	M17yVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXYRlA2UUN3ME20MlI6PjZizszN	NWnpWFVzW0GQR1XS
H-EMC-SS	NYDVZok2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXTS\|B6UUN3ME20MlMyQDNzIN88US=>	NHPsPHhUSU6JRWK=
ES3	NX\aZnR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{eyfmlEPTB;ND6zOVQ1OSEQvF2=	MoDGV2FPT0WU
no-11	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkX4TWM2OD12LkO1OVU1KM7:TR?=	MYfTRW5ITVJ?
LAN-6	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PFcGlEPTB;ND60OVE5QSEQvF2=	MVTTRW5ITVJ?
FTC-133	NF3PSVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTRwNUO5OUDPxE1?	M2DnU3NCVkeHUh?=
8505C	NGizO3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmLJTWM2OD12LkW0NlMh\|ryP	NWXp[pRSW0GQR1XS
SW620	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfZcG5KSzVyPUSuOVcxPTdizszN	M372XXNCVkeHUh?=
BCPAP	M1rFb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjHTWM2OD12Lk[zOFgyKM7:TR?=	NH;Vc5RUSU6JRWK=
SK-LU-1	M17HVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13TUmlEPTB;ND62OlA5QSEQvF2=	NUTJc\|U4W0GQR1XS
NCI-H1623	NGi2fmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTRwN{CyNlgh\|ryP	NGrkVnNUSU6JRWK=
C2BBe1	NFTOc5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTRwN{SwNFgh\|ryP	MX;TRW5ITVJ?
GP5d	MnvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm[1TWM2OD12Lke4N\|g5KM7:TR?=	M{fuT3NCVkeHUh?=
NB6	NEXr[nJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTRwOE[yNFQh\|ryP	MWjTRW5ITVJ?
MDA-MB-157	NUHTSIZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHjTWM2OD12Lki4O\|Yh\|ryP	NUfuVVdMW0GQR1XS
UMC-11	NWHhPFN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTRwOEi5OlQh\|ryP	M2OyeXNCVkeHUh?=
HCC1419	NX3meHg5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGPKOG5KSzVyPUSuPVAxPjNizszN	M1fpXXNCVkeHUh?=
NCI-H2029	M4nPW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;WcmpKSzVyPUSuPVQyQDVizszN	NFrpZplUSU6JRWK=
LXF-289	NHG5ZmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXWNWxKSzVyPUWuNFM4OTlizszN	M2\IXnNCVkeHUh?=
KINGS-1	M1vON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHS4NoJKSzVyPUWuNFc4PDRizszN	Mk\qV2FPT0WU
HD-MY-Z	NXrUOItGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTVwMkO5Olkh\|ryP	MV\TRW5ITVJ?
ESS-1	M4XUcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrtd2dFUUN3ME21MlI2PTl5IN88US=>	M4LLTnNCVkeHUh?=
GI-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4D1VWlEPTB;NT6yO\|kzPiEQvF2=	MkH1V2FPT0WU
RPMI-2650	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\VTWM2OD13LkO2NVYh\|ryP	NH7WV5NUSU6JRWK=
IA-LM	NX;HZpU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{T1NmlEPTB;NT6zPVg4OSEQvF2=	MWfTRW5ITVJ?
KP-4	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTVwNE[zN\|Qh\|ryP	NEH0d\|JUSU6JRWK=
G-402	MnXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTVwNUG4OlUh\|ryP	MlPGV2FPT0WU
OS-RC-2	NGLvSpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPOTWM2OD13LkWyOlA1KM7:TR?=	MVPTRW5ITVJ?
NCI-H1155	NX3oenQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYX4UFNCUUN3ME21MlU1QTV3IN88US=>	NGLaNXVUSU6JRWK=
OE19	MnPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoS3TWM2OD13Lk[4OlI1KM7:TR?=	M4Ht[HNCVkeHUh?=
U-2-OS	NVLvcGwzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37RPGlEPTB;NT64PVAyOyEQvF2=	MULTRW5ITVJ?
SCC-15	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUL4NFZoUUN3ME21Mlk{PjZ{IN88US=>	MkDXV2FPT0WU
NCI-H630	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3fDfmlEPTB;NT65PVQxPCEQvF2=	MXfTRW5ITVJ?
PFSK-1	NITTdY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTZwMEWyOVkh\|ryP	NH3ZUVVUSU6JRWK=
NCI-H1770	NWrlRYVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3lTWM2OD14LkKwPFc1KM7:TR?=	M13iUnNCVkeHUh?=
SK-MEL-3	MnLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XMcWlEPTB;Nj60NlkyPSEQvF2=	M2fPZXNCVkeHUh?=
LB1047-RCC	MlTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTZwNEe2NlUh\|ryP	NEPmUlFUSU6JRWK=
NCI-H446	NEfjWnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTLOnJ5UUN3ME22MlYzQTJ3IN88US=>	MkjSV2FPT0WU
SW780	NEm1cWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDzW3pHUUN3ME22MlcxOTh3IN88US=>	MlH0V2FPT0WU
NEC8	NI\0SGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTn[ItKSzVyPU[uO\|Y3OyEQvF2=	MoLOV2FPT0WU
NOMO-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjxV4JKSzVyPU[uO\|gyOTFizszN	NXmySXpqW0GQR1XS
COLO-668	NH7WS2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4r0XWlEPTB;Nj64OFM5PyEQvF2=	MkP1V2FPT0WU
MC116	M4j5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfWTJJKSzVyPU[uPVM5QTdizszN	NG\GRVRUSU6JRWK=
HCC1937	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2ruOWlEPTB;Nj65PVI2OSEQvF2=	NV;MXpVwW0GQR1XS
NCI-N87	NYnGRZpvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3NZpZKSzVyPUeuNVkzQTNizszN	NVOxPINRW0GQR1XS
COLO-320-HSR	NVPXdFNoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXriNnVsUUN3ME23MlIzPzN6IN88US=>	NH7YR5VUSU6JRWK=
HCC1806	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF61[4FKSzVyPUeuNlYxPDRizszN	MnzEV2FPT0WU
OVCAR-3	NXrYWZRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfYWXNlUUN3ME23MlM{ODN6IN88US=>	MWLTRW5ITVJ?
NUGC-3	M1j1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXzofFBVUUN3ME23MlM6Pjl2IN88US=>	M3PTRXNCVkeHUh?=
SW1783	NIWxNYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjOTWM2OD15LkSzNVc2KM7:TR?=	MYjTRW5ITVJ?
GCT	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnfOTWM2OD15LkW2PVA3KM7:TR?=	NUPafWE{W0GQR1XS
NCI-H2126	NYPadGw3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTdwN{O2NlUh\|ryP	M2T5cnNCVkeHUh?=
MEL-HO	M1frTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTDd2pVUUN3ME23Mlc4ODV2IN88US=>	NGTMXmNUSU6JRWK=
CAPAN-1	Mni3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWTqWZRrUUN3ME23Mlc4OzV5IN88US=>	MV7TRW5ITVJ?
SW756	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DjS2lEPTB;Nz63PFM{OyEQvF2=	MkntV2FPT0WU
SKG-IIIa	NVHZcJAzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXroSJlKUUN3ME23MlgyQDl{IN88US=>	NEHQc5lUSU6JRWK=
HCE-T	NXXNd4g6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXKe\|hWUUN3ME23Mlg4Pzh\|IN88US=>	NHfCZYlUSU6JRWK=
Ca-Ski	MlvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoO0TWM2OD15Lkm5N\|g{KM7:TR?=	NWTYZ4lMW0GQR1XS
COLO-684	M2LWTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRThwMEG4NVgh\|ryP	M1vFbXNCVkeHUh?=
KYSE-70	M2jPcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRThwMEe3Nlkh\|ryP	M33rW3NCVkeHUh?=
TI-73	NWS4V2puT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjoUHdTUUN3ME24MlI2QDVzIN88US=>	MnzkV2FPT0WU
BT-20	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFqwT49KSzVyPUiuNlYxPTJizszN	NFPIdJpUSU6JRWK=
MHH-ES-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRThwNUG4N\|Qh\|ryP	NUW4U4p1W0GQR1XS
TE-12	NXflfolXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDyU\|VKSzVyPUiuOVk6OzFizszN	NIfRSZFUSU6JRWK=
YH-13	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVT0RYdUUUN3ME24MlYyODB6IN88US=>	NGHEeJVUSU6JRWK=
SF126	NUHiTIFLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HifmlEPTB;OD64N\|g3PSEQvF2=	MWTTRW5ITVJ?
J82	NV\NRm5JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPjTWM2OD16LkmwNFM5KM7:TR?=	NH7Bb4JUSU6JRWK=
RCC10RGB	NHm0XVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDRUoVKSzVyPUiuPVk2PjFizszN	NHHvN2hUSU6JRWK=
SK-UT-1	NGXDVIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rTbWlEPTB;OT6wOFk1PSEQvF2=	MojZV2FPT0WU
LB2241-RCC	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTBZ2RVUUN3ME25MlE6OTN5IN88US=>	NF[2PGVUSU6JRWK=
LB996-RCC	NHfre2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTlwMUm4PUDPxE1?	NUn1NnV5W0GQR1XS
EPLC-272H	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3rDTmlEPTB;OT6zO\|Y2PyEQvF2=	MWnTRW5ITVJ?
CTV-1	NHm2TINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVi0V3ZQUUN3ME25MlU3PTN{IN88US=>	MoLoV2FPT0WU
HSC-2	MnH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTlwNUe1OUDPxE1?	MXrTRW5ITVJ?
SK-MEL-28	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXCTWM2OD17Lk[xPFk{KM7:TR?=	NIPtcJhUSU6JRWK=
MMAC-SF	NFnITIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIH2eYFKSzVyPUmuOlg4PSEQvF2=	MljlV2FPT0WU
CP50-MEL-B	M{LtPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33GNGlEPTB;OT63OVc5OiEQvF2=	NFz2NppUSU6JRWK=
HT-1080	NX72XFU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4L5fmlEPTB;OT63O\|c{QSEQvF2=	NUjtOmROW0GQR1XS
HEC-1	NFraV21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlnqTWM2OD1zMD6zN\|UzKM7:TR?=	MYLTRW5ITVJ?
AGS	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkX2TWM2OD1zMD6zO\|Qh\|ryP	MXrTRW5ITVJ?
GAMG	NYTRbmx4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1y2UWlEPTB;MUCuOVE3OiEQvF2=	M4fn[3NCVkeHUh?=
SW48	NYPlUHlET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTFyLkWxPFkh\|ryP	NWixN5hlW0GQR1XS
U031	M3LsVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYrXVJRsUUN3ME2xNE42QTB6IN88US=>	M2ixSnNCVkeHUh?=
OVCAR-5	M2rCVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYrIUoZQUUN3ME2xNE43PDJ7IN88US=>	M4XSbXNCVkeHUh?=
SF295	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTFyLk[3NFQh\|ryP	Mn7FV2FPT0WU
BHT-101	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjJ[llKSzVyPUGwMlcyPzdizszN	NVPLdmJ3W0GQR1XS
VMRC-RCZ	M4PneGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHv5fGlKSzVyPUGxMlMzODFizszN	MWnTRW5ITVJ?
ACHN	NF:1fZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTFzLkSyNVEh\|ryP	NX;BfFZsW0GQR1XS
NCI-H526	NGjkeopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYnSPFlbUUN3ME2xNU42ODR\|IN88US=>	MlP4V2FPT0WU
MN-60	MoT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmi1TWM2OD1zMT61N\|kh\|ryP	NUfxNoR5W0GQR1XS
NCI-H2291	NF3iZ21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEO4cGFKSzVyPUGxMlU1PjZizszN	M2XPN3NCVkeHUh?=
SCC-25	M2n2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7nc\|RKSzVyPUGxMlc2PTZizszN	MlnXV2FPT0WU
SK-MEL-2	NEXkOWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jFOGlEPTB;MUGuO\|Y{PyEQvF2=	MW\TRW5ITVJ?
SN12C	NVzqUIlET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH64XY9KSzVyPUGxMlk{PTVizszN	MkDGV2FPT0WU
NCI-H69	NHPtdWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWrsS5V5UUN3ME2xNk41OjN2IN88US=>	M3O4ZnNCVkeHUh?=
ME-180	MnmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\5[GlEPTB;MUKuO\|A2PCEQvF2=	NVnZVpZVW0GQR1XS
MC-IXC	NH\WUW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo[1TWM2OD1zMj63OVE5KM7:TR?=	NFjlXGRUSU6JRWK=
NCI-H2347	M37zOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjsTWM2OD1zMj63OlE1KM7:TR?=	NVPS[ZZ2W0GQR1XS
M059J	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkDsTWM2OD1zMj63O\|I4KM7:TR?=	NYTuZVhIW0GQR1XS
A2058	NGfYco1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLXW5ZnUUN3ME2xNk45PjhzIN88US=>	NGm2cItUSU6JRWK=
VA-ES-BJ	M3j4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHoV4tKSzVyPUGyMlg4QDVizszN	NFL6flJUSU6JRWK=
Ca9-22	NXf6[IViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTsTWM2OD1zMj65OFUyKM7:TR?=	MU\TRW5ITVJ?
KNS-42	NILxUodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXzUFB3UUN3ME2xNk46QTh2IN88US=>	NXfL[FNkW0GQR1XS
LoVo	NGW3elJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn:5TWM2OD1zMz6yN\|E{KM7:TR?=	NI\HcGpUSU6JRWK=
AM-38	NUjvZWtVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWexcXRLUUN3ME2xN{4zPTZ4IN88US=>	NYXNfY9qW0GQR1XS
NB5	M3nWXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTF\|LkO3OVIh\|ryP	NGX2NYtUSU6JRWK=
L-363	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1XjT2lEPTB;MUOuOFA{OyEQvF2=	NYD5bVI6W0GQR1XS
SK-MEL-30	Mnu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTF2LkC2OFUh\|ryP	MonMV2FPT0WU
NCI-H1563	NVXBSHBmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjuTWM2OD1zND62NFM6KM7:TR?=	NIrnPZBUSU6JRWK=
NCI-H2228	M1\Ee2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnGPYJKSzVyPUG0MlYxPzdizszN	NXr2SW9YW0GQR1XS
MFM-223	NWPSfHNzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HVNGlEPTB;MUWuNVgyOyEQvF2=	M1vKUnNCVkeHUh?=
LB831-BLC	M1P1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fHbGlEPTB;MUWuNlc3PyEQvF2=	NYr1NW52W0GQR1XS
SW872	M4nTO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXmTWM2OD1zNT6zNFg3KM7:TR?=	MX3TRW5ITVJ?
NCI-H522	M2f0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrZe4FKSzVyPUG1MlM{ODZizszN	NE\qdYZUSU6JRWK=
EW-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTPRoxxUUN3ME2xOU42PDZ{IN88US=>	MWPTRW5ITVJ?
HN	NHfpUYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\DOGFvUUN3ME2xOU42QTR{IN88US=>	NVjrRZRmW0GQR1XS
SW837	M1rNSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjKXG5KSzVyPUG1Mlc5PDdizszN	MkHCV2FPT0WU
SCC-9	M1nsW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTF3LkixNVQh\|ryP	NImz[nhUSU6JRWK=
MKN7	NHrVcmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rpSGlEPTB;MUWuPVc{OiEQvF2=	NYn0cWxbW0GQR1XS
KYSE-410	M2P0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnvWTWM2OD1zNj61PVEh\|ryP	NH\1OYxUSU6JRWK=
SK-N-DZ	MkTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHjSndKSzVyPUG2MlYyOTZizszN	M1vVd3NCVkeHUh?=
COR-L105	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXvJR\|UxRTF4Lk[1Nlgh\|ryP	M33nTXNCVkeHUh?=
LB2518-MEL	NG\SfWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4n0OmlEPTB;MU[uPFM5QSEQvF2=	MmfFV2FPT0WU
OVCAR-4	M1W3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGC4TodKSzVyPUG2Mlg5PjJizszN	MVLTRW5ITVJ?
TK10	MnjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLxVmZKSzVyPUG2Mlk1PzNizszN	M{XYcnNCVkeHUh?=
KNS-62	NUS2W45JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1y2N2lEPTB;MU[uPVc4PyEQvF2=	MkO4V2FPT0WU
RPMI-8866	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXvlfYJnUUN3ME2xO{4yPzN{IN88US=>	MmLvV2FPT0WU
HuP-T4	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2DifmlEPTB;MUeuNlQ6PSEQvF2=	NInWfnZUSU6JRWK=
CGTH-W-1	NHn6dXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIezc3pKSzVyPUG3MlUzOTlizszN	MlPrV2FPT0WU
T-24	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIiyeYFKSzVyPUG3MlU{PDdizszN	MoXVV2FPT0WU
HT-3	M4PDbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTF5LkW5NVQh\|ryP	M4H3THNCVkeHUh?=
KS-1	NIPGVoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\lXXJKSzVyPUG3MlY4OyEQvF2=	NGXWXmRUSU6JRWK=
NCI-H1792	NV71NZNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUe3OnpQUUN3ME2xO{44QThizszN	NHSzNWRUSU6JRWK=
ABC-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnnenF3UUN3ME2xO{45OTRzIN88US=>	NHXNT3BUSU6JRWK=
BPH-1	NH;2W5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3ITWM2OD1zOD6xOlg2KM7:TR?=	NVvhOllOW0GQR1XS
A431	NGTTXmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nJcmlEPTB;MUiuOFEzPyEQvF2=	NG\WT2hUSU6JRWK=
T98G	NFHSO4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILVc4ZKSzVyPUG4MlUyPTdizszN	NFTDUFhUSU6JRWK=
BHY	NYDuUXVxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLzTWM2OD1zOD64Olkh\|ryP	MWfTRW5ITVJ?
Capan-2	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTF6LkmwO\|gh\|ryP	MWrTRW5ITVJ?
MDA-MB-175-VII	Ml7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnzkTWM2OD1zOD65NlA6KM7:TR?=	NFfFeINUSU6JRWK=
CAL-27	NHrCNotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zxUGlEPTB;MUmuNFQ5PyEQvF2=	M1jUdHNCVkeHUh?=
AsPC-1	NIna[YVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTF7Lki2OVch\|ryP	MmfiV2FPT0WU
KU812	NIfqblhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnflTWM2OD1zOT65OVc{KM7:TR?=	NXfpfFZIW0GQR1XS
NCI-H441	NVr2fZFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPXNWhIUUN3ME2yNE4xODFizszN	NUfNO4hCW0GQR1XS
Mewo	Ml\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXsU3hGUUN3ME2yNE4yOjh6IN88US=>	M1;hW3NCVkeHUh?=
SK-MEL-24	NE\OPHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUD1VHk3UUN3ME2yNE4yPDd5IN88US=>	M1nMU3NCVkeHUh?=
NCI-H727	NUK2Ro1XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGC3[ZFKSzVyPUKwMlI4ODRizszN	MkHvV2FPT0WU
EKVX	NIDldYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTJyLk[wOkDPxE1?	MoHlV2FPT0WU
RT-112	NFe4cXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTJyLk[xNlIh\|ryP	M3OzNXNCVkeHUh?=
CAMA-1	NXfBTWV3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjoTWM2OD1{MD65PFA{KM7:TR?=	MWrTRW5ITVJ?
SW900	Mni3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGr3cotKSzVyPUKxMlAyPDlizszN	M4T6THNCVkeHUh?=
NCI-H23	NYPp[ZZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXe3NVRCUUN3ME2yNU4yOjd5IN88US=>	NWHMdHoxW0GQR1XS
SK-PN-DW	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrGd49KSzVyPUKxMlE3PDlizszN	M{TG[XNCVkeHUh?=
BB30-HNC	NI\h[mhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\hW4JKSzVyPUKxMlI4PDVizszN	NWixb3NOW0GQR1XS
VM-CUB-1	NFLGdINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\hTWM2OD1{MT6zOVM3KM7:TR?=	M{f1dnNCVkeHUh?=
IST-MEL1	NEHmUW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIj4fINKSzVyPUKxMlM3QTJizszN	M1nQbXNCVkeHUh?=
CTB-1	M2PBZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHezUWZKSzVyPUKxMlQ4PTVizszN	NVrvbGdxW0GQR1XS
LCLC-103H	Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTJ{LkG1PFIh\|ryP	Ml;QV2FPT0WU
PANC-03-27	M2\SUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jOUWlEPTB;MkKuOVE3QSEQvF2=	MknxV2FPT0WU
HTC-C3	MkjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXwWZRKSzVyPUKyMlU2PTVizszN	MU\TRW5ITVJ?
TE-8	M1W5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTJ\|LkK1OlUh\|ryP	MY\TRW5ITVJ?
NCI-H292	Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnWfGFKSzVyPUK1MlM2OzZizszN	NEjMWXdUSU6JRWK=
COLO-680N	MkO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnqTWM2OD1{NT62N\|I6KM7:TR?=	Mn;mV2FPT0WU
KYSE-520	NH;iXWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zwN2lEPTB;MkWuOlQ1KM7:TR?=	MnfBV2FPT0WU
NB10	MmLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTJ4LkOxNVch\|ryP	MYTTRW5ITVJ?
NCI-H661	NUXYfVF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTJ4LkS3NVMh\|ryP	MYHTRW5ITVJ?
GMS-10	MoC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnpcplXUUN3ME2yOk45PjN6IN88US=>	NHHQcIxUSU6JRWK=
NCI-H2122	Ml7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTPfZJ5UUN3ME2yOk46QTl6IN88US=>	NHP0c5dUSU6JRWK=
OVCAR-8	M{jRV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\ZTWM2OD1{Nz6wOlM5KM7:TR?=	MVrTRW5ITVJ?
DJM-1	MkjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LX[GlEPTB;MkeuNVQ2PCEQvF2=	M{T5dXNCVkeHUh?=
UACC-893	M3jRNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTJ5Lkm4O\|gh\|ryP	MWfTRW5ITVJ?
C8166	NWG2WGVKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH30eIJKSzVyPUK4MlY6OzhizszN	NYG1OXpHW0GQR1XS
NCI-H1693	M{OwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPiTWM2OD1{OD62PVc2KM7:TR?=	MWPTRW5ITVJ?
TYK-nu	NHPpXFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTNyLkCzOFUh\|ryP	NXfUWXRIW0GQR1XS
SW1710	NGr3N5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTNyLkGyOkDPxE1?	NE\adGxUSU6JRWK=
A375	M2P0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHTU4ZKSzVyPUOwMlMzPDNizszN	MmLPV2FPT0WU
HMV-II	NYTHZ\|VtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\TRo1KSzVyPUOxMlM2QTJizszN	NHOxTHdUSU6JRWK=
NCI-H2087	M4TkVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{LkXGlEPTB;M{GuOlM2OiEQvF2=	MYTTRW5ITVJ?
CAL-54	NW[wd2lNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTNzLkeyOFEh\|ryP	MYPTRW5ITVJ?
HCC70	NYTkRY5lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{i1NGlEPTB;M{KuNVM5PyEQvF2=	MmfDV2FPT0WU
ES1	NFzBb\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHjudI1KSzVyPUOyMlMxPjJizszN	NUfER3F[W0GQR1XS
NCI-H1355	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PreWlEPTB;M{OuNlA1KM7:TR?=	NUDadlJsW0GQR1XS
CFPAC-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPiTWM2OD1\|Mz6yN\|MzKM7:TR?=	NEjiSWJUSU6JRWK=
MKN28	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnPKTWM2OD1\|Mz6zPFA6KM7:TR?=	M1vNWXNCVkeHUh?=
HDLM-2	M3faemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rnNWlEPTB;M{OuOlk{OSEQvF2=	MnHIV2FPT0WU
PANC-10-05	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlSyTWM2OD1\|ND6xNFE1KM7:TR?=	NEjWb5pUSU6JRWK=
SAS	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXPTJEyUUN3ME2zOE41PTZ3IN88US=>	M1SyR3NCVkeHUh?=
HCC1395	M13uTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTN2LkexPFYh\|ryP	NIDmNXpUSU6JRWK=
8305C	NILMT5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\LVWhKSzVyPUO1Mlg1OTVizszN	M2r2TXNCVkeHUh?=
KM12	NIDKPFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITD[25KSzVyPUO2Mlc2PDdizszN	M4PIVXNCVkeHUh?=
SW1116	M4ezUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTN5LkW5PVIh\|ryP	M{\tOXNCVkeHUh?=
SK-MEL-1	MnrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnKO2dvUUN3ME2zPE4{Ozh7IN88US=>	NW\IRlhYW0GQR1XS
HCC2218	NXPVOXJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3hOFlKSzVyPUO4MlY2OTlizszN	M1;XUHNCVkeHUh?=
T84	MnzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXsTWM2OD1\|OD63OFA6KM7:TR?=	MYnTRW5ITVJ?
ETK-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1H3VmlEPTB;M{muNFIzKM7:TR?=	NXzxb\|V{W0GQR1XS
COLO-800	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnyZ3lbUUN3ME2zPU4{QDZ6IN88US=>	NYLkd\|g5W0GQR1XS
CAL-12T	M4DCPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;HTWM2OD1\|OT61NlgyKM7:TR?=	M3niZ3NCVkeHUh?=
ACN	NEHUPIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XLOWlEPTB;NECuOFkyOSEQvF2=	M1fpOnNCVkeHUh?=
SJSA-1	NFzPOlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTRzLkG1PVYh\|ryP	NVPtSnpDW0GQR1XS
PSN1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPHZ2pKSzVyPUSxMlE4PDlizszN	MYfTRW5ITVJ?
D-566MG	MoXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTRzLkKwPFYh\|ryP	M4DiNnNCVkeHUh?=
EGI-1	NF\wfmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2i1bWlEPTB;NEKuOFI5KM7:TR?=	NX76VHhJW0GQR1XS
A204	Mn7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVyzRoFCUUN3ME20Nk43Ozh6IN88US=>	NYjGc2ZkW0GQR1XS
Saos-2	MoP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTNTWM2OD12Mj64N\|Y6KM7:TR?=	M{PtenNCVkeHUh?=
SNU-C2B	M2DGRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTR\|Lk[4O\|gh\|ryP	NHqz[lBUSU6JRWK=
HLE	NUjifWtrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTYfpUyUUN3ME20OE4xQDV4IN88US=>	M{LndnNCVkeHUh?=
SW1463	NWjFZYRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\STWM2OD12ND65PVcyKM7:TR?=	M13GPHNCVkeHUh?=
DSH1	NEPiZ4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHrNW12UUN3ME20OU4xODN\|IN88US=>	Mn\EV2FPT0WU
MCF7	NVXIbXVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLz[\|dmUUN3ME20OU42ODVzIN88US=>	MlrXV2FPT0WU
K5	MoTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUXQcGR{UUN3ME20OU46PDB3IN88US=>	NF\6clJUSU6JRWK=
NCI-H358	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\uWWM4UUN3ME20O{4zOTVizszN	M2DMcHNCVkeHUh?=
NCI-H2030	M3HtNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTR5LkKzO\|Qh\|ryP	NIjse5ZUSU6JRWK=
SW948	NVPzS49bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\zTWM2OD12Nz60OlQh\|ryP	MXzTRW5ITVJ?
BALL-1	NFvLXXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTR5Lk[xOlgh\|ryP	Mof6V2FPT0WU
TE-9	M1nnN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7rc\|FxUUN3ME20O{46PThzIN88US=>	NFvoOHlUSU6JRWK=
SK-N-FI	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLvT2ZqUUN3ME20PE4xOzV6IN88US=>	M{P1e3NCVkeHUh?=
KALS-1	Mn;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LIdWlEPTB;NEiuNVI5QSEQvF2=	MVPTRW5ITVJ?
HO-1-N-1	NFPFN5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofUTWM2OD12OD63OFQ2KM7:TR?=	M{LpfnNCVkeHUh?=
NCI-H2452	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTR7LkGxOVIh\|ryP	MlnsV2FPT0WU
OC-314	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTR7Lk[4N\|Qh\|ryP	MoX1V2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	STAT3 / pSTAT3 / STAT6 / pSTAT6 / Mcl-1 / Cleaved Mcl-1 / Bcl-xl / Bim / puma / Bik / Bax / PARP / c-Myc; PubMed: 26811457 Proc Natl Acad Sci U S A (A) Western blot analysis of expressions of STAT3/p-STAT3 and STAT6/p-STAT6 as well as antiapoptotic members (Bcl-2, Bcl-xL, and Mcl-1) after 48 h of treatments in HDLM-2 cells. (B) Western blot analysis of expressions of proapoptotic proteins (Bim, Puma, Bik, Bax, and p-Bad) as well as caspase cascade molecules (PARP and c-Myc) after 48 h of treatments. β-Actin was used as an input control. caspase3 / cleaved caspase 3; PubMed: 24481442 Cell Death Dis (b) (i) N/TERT, (ii) SINCE and (iii) SINEG2 cells were either untreated (0 μM/DMSO) or treated with increasing doses of Navitoclax (ABT-263; 0.025–30 μM) and were incubated for 24 h. Next, cells were collected and whole-cell lysates were prepared and immunoblotted against anti-full-length Caspase 3 (∼35 kDa) antibody, whereas β-actin (∼42 kDa) was used as a protein-loading control. Apoptosis was assessed through detecting the cleaved bands of Caspase-3 (∼19, 17 kDa).	26811457 24481442
Growth inhibition assay	Cell viability; PubMed: 25685063 Cancer Cell Int (C) Hcc827, (D) H292, and (E) H1993 cells were treated with increasing concentrations of albendazole or mebendazole in the presence of navitoclax (0, 1, 2, and 4 μM). Viability was determined after 1 day.	25685063

In vivo

When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. ^[2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. ^[2]

Protocol

Kinase Assay: ^[1]	+ Expand Affinity determination: Binding affinities (K_i or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research: ^[1]	+ Expand Cell lines: SCLC cell lines Concentrations: 0-1 μM Incubation Time: 48 hours Method: Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO₂. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 ⁴) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed. (Only for Reference)
Animal Research: ^[1]	+ Expand Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG Dosages: 100 mg/kg/d Administration: Administered via p.o. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (102.6 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+corn oil For best results, use promptly after mixing.	7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Navitoclax (ABT-263) SDF

Molecular Weight	974.61
Formula	C₄₇H₅₅ClF₃N₅O₆S₃
CAS No.	923564-51-6
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03181126	Recruiting	Drug: Navitoclax\|Drug: Chemotherapy\|Drug: Venetoclax	Acute Lymphoblastic Leukemia (ALL)\|Lymphoblastic Lymphoma	AbbVie	November 27 2017	Phase 1
NCT02520778	Recruiting	Drug: Navitoclax\|Drug: Osimertinib	Advanced Lung Non-Squamous Non-Small Cell Carcinoma\|EGFR Exon 19 Deletion Mutation\|EGFR NP_005219.2:p.L858R\|EGFR NP_005219.2:p.T790M\|Metastatic Lung Non-Squamous Non-Small Cell Carcinoma\|Stage III Lung Non-Small Cell Cancer AJCC v7\|Stage IIIA Lung Non-Small Cell Cancer AJCC v7\|Stage IIIB Lung Non-Small Cell Cancer AJCC v7\|Stage IV Lung Non-Small Cell Cancer AJCC v7	National Cancer Institute (NCI)	March 31 2016	Phase 1
NCT02591095	Completed	Drug: ABT-263	Platinum-resistant or Refractory Ovarian Cancer	Centre Francois Baclesse\|ARCAGY/ GINECO GROUP\|French Cancer Research Hospital Program	January 2016	Phase 2
NCT02079740	Recruiting	Biological: Navitoclax\|Drug: Trametinib	Advanced Malignant Solid Neoplasm\|Malignant Female Reproductive System Neoplasm\|Metastatic Malignant Solid Neoplasm\|Recurrent Lung Carcinoma\|Recurrent Malignant Solid Neoplasm\|Recurrent Pancreatic Carcinoma\|Stage III Lung Cancer AJCC v7\|Stage III Pancreatic Cancer AJCC v6 and v7\|Stage IV Lung Cancer AJCC v7\|Stage IV Pancreatic Cancer AJCC v6 and v7\|Unresectable Malignant Solid Neoplasm	National Cancer Institute (NCI)	March 7 2014	Phase 1\|Phase 2
NCT00887757	Completed	Drug: ABT-263\|Drug: gemcitabine	Solid Tumors	AbbVie\|Genentech Inc.	September 2009	Phase 1
NCT00888108	Completed	Drug: ABT-263\|Drug: Docetaxel	Solid Tumor	Abbott\|Genentech Inc.	July 2009	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?
Answer:
S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.
Question 2:
Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?
Answer:
According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Selective Bcl-2 Inhibitor

ABT-199 (GDC-0199) : Bcl-2-selective, K_i<0.01 nM.
Bcl-2 Inhibitor in Clinical Trial

Obatoclax Mesylate (GX15-070) : Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.
Newest Bcl-2 Family Activator

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.
Classic Bcl-2 Inhibitor

ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

Related Bcl-2 Products

A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
Venetoclax (ABT-199, GDC-0199)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

Features:Re-engineered version of ABT-263 (Navitoclax).
ABT-737

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
UMI-77

UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
Obatoclax Mesylate (GX15-070)

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Features:Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.
TW-37

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Sabutoclax

Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
AT101

AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Navitoclax (ABT-263)

Cited by 93 Publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Navitoclax (ABT-263) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Choose Your Country or Region

By Signaling Pathways

By product type

Navitoclax (ABT-263)

Cited by 93 Publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Navitoclax (ABT-263) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)